Hot Pursuit
Divis Laboratories slipped 3.27% to Rs 6,199.50 after the pharma major's consolidated net profit declined 17.67% to Rs 545 crore in Q1 FY26 as against Rs 662 crore recorded in Q4 FY25.
Revenue from operations also declined 6.79% quarter on quarter (QoQ) to Rs 2,410 crore for the quarter ended 30 June 2025
On a year-on-year (YoY) basis, the company's net profit rose 26.74%, while revenue increased 13.78%, indicating continued growth over the previous year despite the sequential decline.
Profit before tax for the quarter stood at Rs 733 crore, down 15.16% QoQ but up 21.35% YoY.
The company reported a forex gain of Rs 39 crore during the quarter, compared to a forex loss of Rs 1 crore in the corresponding quarter of the previous financial year.
On a standalone basis, the company's net profit surged 29.53% to Rs 557 crore on a 14.25% rise in revenue to Rs 2,357 crore in Q1 FY26 over Q1 FY25.
Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.
Powered by Capital Market - Live News